# Domainex

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/domainex

- Industry: Biotechnology
- Headquarters: Essex, UK
- Website: www.domainex.co.uk
- Total disclosed funding: $2.6M
- Latest round: Series A (Apr 4, 2008)
- Investors on record: 2

## About

Domainex Ltd is a UK-based company focused on integrated drug discovery services, offering tailored solutions to pharmaceutical and biotechnology clients to enhance drug development processes.Founded in 2002, Domainex Ltd specializes in drug discovery services, providing innovative solutions to the pharmaceutical and biotechnology sectors. Headquartered in Essex, UK, the company has secured a total of 6 deals to date, with the latest funding round completed on January 23, 2018. This round was a Grant amounting to GBP 0.120 mn, led by Innovate UK, contributing to a total amount raised of GBP 1.530 mn. The founders, David Madge and David Selwood, have established a strong background in life sciences.Domainex specializes in integrated drug discovery services, focusing on a comprehensive range of solutions tailored to meet the needs of pharmaceutical and biotechnology clients. The company’s core offerings include medicinal chemistry, biophysical assays, and structural biology, facilitating the identification, optimization, and development of drug candidates. Notable technologies such as the Direct-to-Biology (D2B) platform enhance the efficiency of drug discovery by enabling rapid biological screening of compounds, while the PoLiPa technology provides stabilization of membrane proteins for analysis in their native state. Domainex serves a diverse client base, including organizations engaged in oncology, CNS drug discovery, immuno-oncology, and other therapeutic areas, with a significant presence in North America and Europe.In the most recent financial year 2024, Domainex reported a revenue of GBP 14,106,817.70 and an EBITDA of GBP -378,081, reflecting their operations in the B2B market with pharmaceutical and biotechnology companies, engaging in project-based agreements and long-term collaborations for drug discovery services.Domainex plans to leverage the GBP 0.120 mn grant funding received in January 2018 to further enhance its drug discovery capabilities. The company aims to develop new products centered around its proprietary technologies and expand into new geographic markets, particularly in North America and Europe, by 2025. This strategic expansion is intended to strengthen their service offerings and increase their market presence.

## Funding rounds

- Series A, Apr 4, 2008, $2.6M — YFM Equity Partners, Longbow

## Investors

- YFM Equity Partners (https://capitalatlas.ai/funds/yfm-equity-partners) — Series A
- Longbow (https://capitalatlas.ai/funds/longbow) — Series A